← Targeted Therapeutics
Specialty therapeutic
Phelinun (melphalan)
A melphalan-based specialty medicine listed in Ribicon’s former therapeutic portfolio.
Product overview
What it is.
- A cancer medicine used on its own or with other cancer medicines, radiotherapy, or both.
- Listed uses: multiple myeloma, acute lymphoblastic leukemia and acute myeloid leukemia; Hodgkin and non-Hodgkin lymphomas; childhood neuroblastoma; ovarian cancer; and mammary adenocarcinoma, a type of breast cancer.
- Also used with other cytotoxic medicines as conditioning treatment before stem-cell transplantation in adults and children with blood cancers and some other blood disorders in children.
Specifications
Key figures.
- Strengths listed
- 50 mg, 200 mg
Portfolio information
From the original portfolio.
Content review draft
The former site describes oncology and transplantation-related uses. Current Canadian availability, labeling, and indications require confirmation.
This page preserves the former site’s product information for review. It does not establish current Canadian availability, approved indications, performance, or prescribing information. Request verified documentation before relying on it.
Request verified informationExplore this area